To evaluate the effects of the treatment of HMA plus VEN on circulating immune cell repertoire, we first analyzed CD4+ and CD8+ T cell subsets in the PB of AML patients during treatment, compared to PB examined before treatment (baseline). The gene discussed is CD8A; the disease is acute myeloid leukemia.